SynthesisInvestigational new drugs2025

Low-dose PD-1 inhibition in relapsed/refractory classic Hodgkin lymphoma: systematic review and meta-analysis.

Mobil Akhmedov et al.PubMed ↗Publisher ↗

No numbers read from the abstract.